Parasitic worms, seen here, cause river blindness when transmitted to humans by flies
Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.
New funding from the Global Health Innovative Technology Fund will allow scientists from the University of Liverpool’s Department of Chemistry, together with colleagues at the Liverpool School of Tropical Medicine and Japanese pharmaceutical company, Eisai, to develop new medication which is targeted at the bacteria Wolbachia.
River blindness (onchocerciasis) and elephantiasis (lymphatic filariasis) are caused by parasitic worms, and previous attempts to cure these diseases have focused on developing drugs to kill these parasites.
Left untreated, river blindness, where the worms are transmitted by flies, can leave people robbed of their sight, whereas elephantiasis, transmitted by mosquitos, causes extreme swelling in the limbs and genitals.
Attacking these bacteria causes the worms to die slowly or become sterile. The team, known as the Anti-Wolbachia Consortium (A.WOL), has already shown that a four to six week course of the antibiotic, doxycycline can deplete Wolbachia from parasitic worms to cure infection, which has led to the adoption of this treatment in many areas of the world.
The new funding will allow the creation of drugs which can be used in children and pregnant women and can be effective over the course of a week.
The development of the new drugs was achieved by screening over 60,000 compounds to test their ability to kill Wolbachia. With the new funding, the most promising drug candidates will proceed through advanced rounds of chemical modification and testing to identify compounds that have a good safety and efficacy profiles, ready to move into pre-clinical testing.
Medicinal chemist, Professor Paul O’Neill from the University said: “The relationship between these worms and the bacteria is their weakness.
“By targeting the Wolbachia we can safely remove the worms and the disease, and with a quicker acting drug, we can also develop a medicine which is more useful in areas where resources are scarcer and budgets tighter.”
You must be logged in to post a comment.
All recent news
New VG&M exhibition: The Errant Muse
Being Human: The truths about Empire that museums don’t want to tell you
Planned Industrial Action
Take part in our IT survey for your chance to win an iPad Mini
Study launched to identify early warning signs of deterioration in children
Liverpool students join the bill with global star Tom Walker, as UK Music launch major new report on the music industry.
Read more here: http://bit.ly/374kv6A
#MAP #TalentPipeline #MusicByNumbers
Big congrats to Dr Hay Wong for scooping two awards at last night's IET Innovation Awards ceremony @livunieng
The results of this four-year vaccine trial supported by our equine vets have thrown up new information to help scientists gain a better understanding of the condition. Read more in @horseandhound